Jasper Therapeutics (JSPR) Stock Price, News & Analysis

Company Overview

Jasper Therapeutics, Inc. (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation. In parallel, Jasper is advancing JN-6000, an extended-release formulation of tacrolimus aimed at reducing the toxicity and dosing complexities associated with conventional immunosuppressive regimens. The company is also investigating JN-403, a small-molecule agent intended to prevent and treat vaso-occlusive crises in sickle cell disease.

Since its founding, Jasper Therapeutics has established collaborations with leading academic institutions and biotechnology partners to support its clinical programs and expand its platform capabilities. The company is headquartered in Tarrytown, New York, and maintains research activities in key U.S. biotech hubs. Jasper’s leadership team brings together expertise in translational medicine, clinical development, and regulatory affairs to guide its efforts from early-stage discovery through pivotal studies.

With a strategic focus on leveraging immunological insights to design targeted therapies, Jasper Therapeutics aims to deliver novel treatment options for patients experiencing life-threatening disorders. Its ongoing clinical trials and preclinical initiatives reflect a commitment to advancing scientific innovation in areas where current therapeutic choices are limited.

Key Stats

• Today's Range: $2.68 to $2.78
• 50-Day Range: $2.45 to $7.04
• 52-Week Range: $2.27 to $26.05
• Volume: 115,573 shs
• Average Volume: 192,104 shs
• Market Capitalization: $44.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.75
• Consensus Rating: Moderate Buy

Jasper Therapeutics Stock Analysis - MarketRank™

Jasper Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 583rd out of 928 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Jasper Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Jasper Therapeutics has a consensus price target of $28.75, representing about 957.0% upside from its current price of $2.72.

Amount of Analyst Coverage

Jasper Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Jasper Therapeutics are expected to decrease in the coming year, from ($4.47) to ($4.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Jasper Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Jasper Therapeutics is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Jasper Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.03% of the float of Jasper Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Jasper Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Jasper Therapeutics has recently decreased by 4.65%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Jasper Therapeutics does not currently pay a dividend.

Dividend Growth

Jasper Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.03% of the float of Jasper Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Jasper Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Jasper Therapeutics has recently decreased by 4.65%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 9 people have searched for JSPR on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Jasper Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Jasper Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of Jasper Therapeutics is held by insiders.

Percentage Held by Institutions

79.85% of the stock of Jasper Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JSPR Stock Analysis - Frequently Asked Questions

How have JSPR shares performed this year?

Jasper Therapeutics' stock was trading at $21.38 at the beginning of 2025. Since then, JSPR shares have decreased by 87.3% and is now trading at $2.72.

How were Jasper Therapeutics' earnings last quarter?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) posted its earnings results on Wednesday, August, 13th. The company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.20) by $0.54.

When did Jasper Therapeutics' stock split?

Jasper Therapeutics's stock reverse split before market open on Thursday, January 4th 2024.The 1-10 reverse split was announced on Thursday, January 4th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Jasper Therapeutics' major shareholders?

Jasper Therapeutics' top institutional investors include Bank of America Corp DE (1.95%), Bank of Montreal Can (1.05%), Jane Street Group LLC (0.88%) and Geode Capital Management LLC (0.87%). Insiders that own company stock include Velan Capital Investment Manag, Carlyle Group Inc, Holding Ltd Roche, Jeetinder Singh Mahal, Thomas G Wiggans and Anna Louise French.
View institutional ownership trends.

How do I buy shares of Jasper Therapeutics?

Shares of JSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Jasper Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Jasper Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:JSPR
• CIK: 1788028
• Web: jaspertherapeutics.com
• Phone: 650-549-1400
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Jasper Therapeutics: $28.75
• High Price Target: $65.00
• Low Price Target: $5.00
• Potential Upside/Downside: +957.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.60
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($6.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$71.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -172.28%
• Return on Assets: -128.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.10
• Quick Ratio: 2.10

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.11 per share
• Price / Book: 0.66

Miscellaneous

• Outstanding Shares: 16,250,000
• Free Float: 15,505,000
• Market Cap: $44.20 million
• Optionable: Optionable
• Beta: 2.77